Pulmonary arterial hypertension in adults: Novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Rosanio, Salvatore ^a   Pelliccia, Francesco ^b   Gaudio, Carlo ^b   Greco, Cesare ^b   Keylani, Abdul M ^a   D'Agostino, Darrin C ^a  

^a Fort Worth Texas College of Osteopathic Medicine   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; GUANYLATE CYCLASE ACTIVATOR; ILOPROST; IMATINIB; MACITENTAN; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; RHO KINASE INHIBITOR; SELEXIPAG; SILDENAFIL; TADALAFIL; TREPROSTINIL; VASOACTIVE INTESTINAL POLYPEPTIDE; GUANYLATE CYCLASE; PROSTAGLANDIN;

ADULT; BALLOON DILATATION; CATHETER ABLATION; ENDOTHELIAL PROGENITOR CELL; EXERCISE TOLERANCE; FOOD AND DRUG ADMINISTRATION; HUMAN; PROGNOSIS; PULMONARY ARTERY CATHETER; PULMONARY HYPERTENSION; RADIOFREQUENCY ABLATION; REVIEW; SYSTEMATIC REVIEW; DRUG EFFECTS; HYPERTENSION, PULMONARY; PATHOLOGY; PULMONARY ARTERY; UNITED STATES;

CATHETER ABLATION; ENDOTHELIN RECEPTOR ANTAGONISTS; GUANYLATE CYCLASE; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE 5 INHIBITORS; PROSTAGLANDINS; PULMONARY ARTERY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84903592110     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/743868     Document Type: Review

References (106)

1. Galiè N., Rubin L., Pulmonary arterial hypertension. Epidemiology, pathobiology, assessment and therapy. Journal of the American College of Cardiology 2004 43 S1 S90
2. Humbert M., Sitbon O., Chaouat A., Bertocchi M., Habib G., Gressin V., Yaici A., Weitzenblum E., Cordier J., Chabot F., Dromer C., Pison C., Reynaud-Gaubert M., Haloun A., Laurent M., Hachulla E., Simonneau G., Pulmonary arterial hypertension in France: results from a national registry. The American Journal of Respiratory and Critical Care Medicine 2006 173 9 1023 1030 2-s2.0-33646269035 10.1164/rccm.200510-1668OC
3. Peacock A. J., Murphy N. F., McMurrey J. J. V., Caballero L., Stewart S., An epidemiological study of pulmonary arterial hypertension. European Respiratory Journal 2007 30 1 104 109 2-s2.0-34447546600 10.1183/09031936. 00092306 (Pubitemid 47074013)
4. Benza R. L., Miller D. P., Barst R. J., Badesch D. B., Frost A. E., McGoon M. D., An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry. Chest 2012 142 2 448 456 2-s2.0-84863519076 10.1378/chest.11-1460
5. Galiè N., Hoeper M., Humbert M., Guidelines on diagnosis and treatment of pulmonary hypertension: the task force on diagnosis and treatment of pulmonary hypertension of the European society of cardiology and of the European respiratory society. European Heart Journal 2009 30 20 2493 2537 10.1093/eurheartj/ehp297
6. Simmonneau G., Gatzoulis M. A., Adatia I., Updated clinical classification of pulmonary hypertension. Journal of the American College of Cardiology 2013 62 D34 D41
7. Farber H. W., Loscalzo J., Mechanisms of disease: pulmonary arterial hypertension. The New England Journal of Medicine 2004 351 16 1655 1665 2-s2.0-5344233478 10.1056/NEJMra035488 (Pubitemid 39350426)
8. Giaid A., Saleh D., Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. The New England Journal of Medicine 1995 333 4 214 221 2-s2.0-0029055964 10.1056/ NEJM199507273330403
9. Giaid A., Yanagisawa M., Langleben D., Michel R. P., Levy R., Shennib H., Kimura S., Masaki T., Duguid W. P., Stewart D. J., Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. The New England Journal of Medicine 1993 328 24 1732 1739 2-s2.0-0027324745 10.1056/NEJM199306173282402 (Pubitemid 23170122)
10. Christman B. W., McPherson C. D., Newman J. H., King G. A., Bernard G. R., Groves B. M., Loyd J. E., An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. The New England Journal of Medicine 1992 327 2 70 75 2-s2.0-0026628265
11. Humbert M., Morrell N. W., Archer S. L., Cellular and molecular pathobiology of pulmonary arterial hypertension. Journal of the American College of Cardiology 2004 43 13S 24S (Pubitemid 38759713)
12. Laks M. M., Juratsch C. E., Garner D., Beazell J., Criley J. M., Acute pulmonary artery hypertension produced by distention of the main pulmonary artery in the conscious dog. Chest 1975 68 6 807 813 2-s2.0-0016649592
13. Juratsch C. E., Jengo J. A., Castagna J., Laks M. M., Experimental pulmonary hypertension produced by surgical and chemical denervation of the pulmonary vasculature. Chest 1980 77 4 525 530 2-s2.0-0018834910 (Pubitemid 10148425)
14. Osorio J., Russek M., Reflex changes on the pulmonary and systemic pressures elicited by stimulation of baroreceptors in the pulmonary artery. Circulation Research 1962 10 664 667 2-s2.0-0008498169
15. Aramendia P., Taguini C. M., Fourcade A., Taguini A. C., Reflex vasomotor activity during unilateral occlusion of the pulmonary artery. The American Heart Journal 1963 66 1 53 60 2-s2.0-50549156226
16. Hyman A. L., Pulmonary vasoconstriction due to nonocclusive distention of large pulmonary arteries in the dog. Circulation Research 1968 23 3 401 413 2-s2.0-0014325869
17. Chen S. L., Zhang Y. J., Zhou L., Xie D., Zhang F., Jia H., Wong S. S., Kwan T. W., Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo. EuroIntervention 2013 9 2 269 275 2-s2.0-84874923020 10.4244/EIJV9I2A43
18. Jones D. A., Benjamin C. W., Linseman D. A., Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Molecular Pharmacology 1995 48 5 890 896 2-s2.0-0028839874
19. Galiè N., Manes A., Branzi A., Prostanoids for pulmonary arterial hypertension. The American Journal of Respiratory Medicine 2003 2 2 123 137 2-s2.0-0041353958 (Pubitemid 37062722)
20. Rubin L. J., Mendoza J., Hood M., McGoon M., Barst R., Williams W. B., Diehl J. H., Crow J., Long W., Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Annals of Internal Medicine 1990 112 7 485 491 2-s2.0-0025356811 (Pubitemid 20100285)
21. Barst R. J., Rubin L. J., Long W. A., McGoon M. D., Rich S., Badesch D. B., Groves B. M., Tapson V. F., Bourge R. C., Brundage B. H., Koerner S. K., Langleben D., Keller C. A., Murali S., Uretsky B. F., Clayton L. M., Jöbsis M. M., Blackburn S. D., Shortino D., Crow J. W., A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The New England Journal of Medicine 1996 334 5 296 302
22. Badesch D. B., Tapson V. F., McGoon M. D., Brundage B. H., Rubin L. J., Wigley F. M., Rich S., Barst R. J., Barrett P. S., Kral K. M., Jöbsis M. M., Loyd J. E., Murali S., Frost A., Girgis R., Bourge R. C., Ralph D. D., Elliott C. G., Hill N. S., Langleben D., Schilz R. J., McLaughlin V. V., Robbins I. M., Groves B. M., Shapiro S., Medsger T. A. Jr., Gaine S. P., Horn E., Decker J. C., Knobil K., Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Annals of Internal Medicine 2000 132 6 425 434 2-s2.0-17144452827 (Pubitemid 30149039)
23. Olschewski H., Simonneau G., Galiè N., Inhaled iloprost in severe pulmonary hypertension. The New England Journal of Medicine 2002 347 5 322 329 10.1056/NEJMoa020204 (Pubitemid 34815354)
24. Simonneau G., Barst R. J., Galiè N., Naeije R., Rich S., Bourge R. C., Keogh A., Oudiz R., Frost A., Blackburn S. D., Crow J. W., Rubin L. J., Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. The American Journal of Respiratory and Critical Care Medicine 2002 165 6 800 804 2-s2.0-0037086133 (Pubitemid 34229650)
25. McLaughlin V. V., Benza R. L., Rubin L. J., Channick R. N., Voswinckel R., Tapson V. F., Robbins I. M., Olschewski H., Rubenfire M., Seeger W., Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. Journal of the American College of Cardiology 2010 55 18 1915 1922 2-s2.0-77952301237 10.1016/j.jacc.2010.01.027
26. Jing Z. C., Parikh K., Pulido T., Jerjes-Sanchez C., White R. J., Allen R., Torbicki A., Xu K., Yehle D., Laliberte K., Arneson C., Rubin L. J., Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013 127 5 624 633 2-s2.0-84873566367 10.1161/CIRCULATIONAHA.112.124388
27. Channick R. N., Simonneau G., Sitbon O., Robbins I. M., Frost A., Tapson V. F., Badesch D. B., Roux S., Rainisio M., Bodin F., Rubin L. J., Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. The Lancet 2001 358 9288 1119 1123 2-s2.0-0035818316 10.1016/S0140-6736(01)06250-X (Pubitemid 32971843)
28. Rubin L. J., Badesch D. B., Barst R. J., Galiè N., Black C. M., Keogh A., Pulido T., Frost A., Roux S., Leconte I., Landzberg M., Simonneau G., Bosentan therapy for pulmonary arterial hypertension. The New England Journal of Medicine 2002 346 12 896 903 2-s2.0-0037149718 10.1056/NEJMoa012212 (Pubitemid 34984638)
29. Galiè N., Rubin L., Hoeper M., Jansa P., Al-Hiti H., Meyer G., Chiossi E., Kusic-Pajic A., Simonneau G., Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. The Lancet 2008 371 9630 2093 2100 2-s2.0-45249119855 10.1016/S0140-6736(08)60919-8 (Pubitemid 351902178)
30. Galiè N., Olschewski H., Oudiz R. J., Torres F., Frost A., Ghofrani H. A., Badesch D. B., McGoon M. D., McLaughlin V. V., Roecker E. B., Gerber M. J., Dufton C., Wiens B. L., Rubin L. J., Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-Blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008 117 23 3010 3019 2-s2.0-46449124591 10.1161/CIRCULATIONAHA.107.742510
31. Pulido T., Adzerikho I., Channick R. N., Delcroix M., Galiè N., Ghofrani H., Jansa P., Jing Z., Le Brun F., Mehta S., Mittelholzer C. M., Perchenet L., Sastry B. K. S., Sitbon O., Souza R., Torbicki A., Zeng X., Rubin L. J., Simonneau G., Macitentan and morbidity and mortality in pulmonary arterial hypertension. The New England Journal of Medicine 2013 369 9 809 818 2-s2.0-84883108940 10.1056/NEJMoa1213917
32. Galiè N., Ghofrani H. A., Torbicki A., Barst R. J., Rubin L. J., Badesch D., Fleming T., Parpia T., Burgess G., Branzi A., Grimminger F., Kurzyna M., Simonneau G., Sildenafil citrate therapy for pulmonary arterial hypertension. The New England Journal of Medicine 2005 353 20 2148 2157 2-s2.0-26444534291 10.1056/NEJMoa050010 (Pubitemid 41653106)
33. Galiè N., Brundage B. H., Ghofrani H. A., Oudiz R. J., Simonneau G., Safdar Z., Shapiro S., White R. J., Chan M., Beardsworth A., Frumkin L., Barst R. J., Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009 119 22 2894 2903 2-s2.0-67649523052 10.1161/CIRCULATIONAHA.108.839274
34. Ghofrani H., Galiè N., Grimminger F., Grünig E., Humbert M., Jing Z., Keogh A. M., Langleben D., Kilama M. O., Fritsch A., Neuser D., Rubin L. J., Riociguat for the treatment of pulmonary arterial hypertension. The New England Journal of Medicine 2013 369 4 330 340 2-s2.0-84880721470 10.1056/NEJMoa1209655
35. Ghofrani H. A., D'Armini A. M., Grimminger F., Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. The New England Journal of Medicine 2013 369 4 319 329 10.1056/NEJMoa1209657
36. Stewart D. J., Levy R. D., Cernacek P., Langleben D., Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Annals of Internal Medicine 1991 114 6 464 469 2-s2.0-0026034713
37. Galié N., Manes A., Branzi A., The endothelin system in pulmonary arterial hypertension. Cardiovascular Research 2004 61 2 227 237 2-s2.0-0346492721 10.1016/j.cardiores.2003.11.026 (Pubitemid 38091763)
38. Gatfield J., Grandjean C. M., Sasse T., Clozel M., Nayler O., Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS ONE 2012 7 10 2-s2.0-84867562420 10.1371/journal.pone.0047662 e47662
39. Wharton J., Strange J. W., Møller G. M. O., Growcott E. J., Ren X., Franklyn A. P., Phillips S. C., Wilkins M. R., Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. The American Journal of Respiratory and Critical Care Medicine 2005 172 1 105 113 2-s2.0-21544444144 10.1164/rccm.200411-1587OC (Pubitemid 40923321)
40. Tantini B., Manes A., Fiumana E., Pignatti C., Guarnieri C., Zannoli R., Branzi A., Galié N., Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Research in Cardiology 2005 100 2 131 138 2-s2.0-14944356027 10.1007/s00395-004-0504-5 (Pubitemid 40361605)
41. Ghofrani H. A., Voswinckel R., Reichenberger F., Olschewski H., Haredza P., Karadaş B., Schermuly R. T., Weissmann N., Seeger W., Grimminger F., Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. Journal of the American College of Cardiology 2004 44 7 1488 1496 2-s2.0-4644232338 10.1016/j.jacc.2004.06.060 (Pubitemid 39303954)
42. Rubin L. J., Badesch D. B., Fleming T. R., Galiè N., Simonneau G., Ghofrani H. A., Oakes M., Layton G., Serdarevic-Pehar M., McLaughlin V. V., Barst R. J., Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 2011 140 5 1274 1283 2-s2.0-80052088060 10.1378/chest.10-0969
43. Grimminger F., Weimann G., Frey R., Voswinckel R., Thamm M., Bölkow D., Weissmann N., Mück W., Unger S., Wensing G., Schermuly R. T., Ghofrani H. A., First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. European Respiratory Journal 2009 33 4 785 792 2-s2.0-63849256355 10.1183/09031936.00039808
44. Stasch J., Pacher P., Evgenov O. V., Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011 123 20 2263 2273 2-s2.0-79958128614 10.1161/CIRCULATIONAHA.110.981738
45. Humbert M., Barst R. J., Robbins I. M., Channick R. N., Galiè N., Boonstra A., Rubin L. J., Horn E. M., Manes A., Simonneau G., Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. European Respiratory Journal 2004 24 3 353 359 2-s2.0-4544383466 10.1183/09031936.04.00028404 (Pubitemid 39232254)
46. McLaughlin V. V., Oudiz R. J., Frost A., Tapson V. F., Murali S., Channick R. N., Badesch D. B., Barst R. J., Hsu H. H., Rubin L. J., Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. The American Journal of Respiratory and Critical Care Medicine 2006 174 11 1257 1263 2-s2.0-33845526777 10.1164/rccm.200603-358OC (Pubitemid 44924827)
47. Simonneau G., Rubin L. J., Galié N., Barst R. J., Fleming T. R., Frost A. E., Engel P. J., Kramer M. R., Burgess G., Collings L., Cossons N., Sitbon O., Badesch D. B., Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Annals of Internal Medicine 2008 149 8 521 530 2-s2.0-70349099618
48. Hoeper M. M., Taha N., Bekjarova A., Gatzke R., Spiekerkoetter E., Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. European Respiratory Journal 2003 22 2 330 334 2-s2.0-0041742185 10.1183/09031936.03.00008003 (Pubitemid 36987006)
49. Ghofrani H. A., Rose F., Schermuly R. T., Olschewski H., Wiedemann R., Kreckel A., Weissmann N., Ghofrani S., Enke B., Seeger W., Grimminger F., Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. Journal of the American College of Cardiology 2003 42 1 158 164 2-s2.0-0037868048 10.1016/S0735-1097(03)00555-2 (Pubitemid 36760778)
50. Gomberg-Maitland M., McLaughlin V., Gulati M., Rich S., Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. The American Journal of Cardiology 2005 96 9 1334 1336 2-s2.0-27144440344 10.1016/j.amjcard.2005.06.083 (Pubitemid 41505420)
51. Hoeper M. M., Faulenbach C., Golpon H., Winkler J., Welte T., Niedermeyer J., Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. European Respiratory Journal 2004 24 6 1007 1010 2-s2.0-10444246635 10.1183/09031936.04.00051104 (Pubitemid 39642293)
52. Mathai S. C., Girgis R. E., Fisher M. R., Champion H. C., Housten-Harris T., Zaiman A., Hassoun P. M., Additon of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. European Respiratory Journal 2007 29 3 469 475 2-s2.0-33847743922 10.1183/09031936.00081706 (Pubitemid 46372092)
53. Zhu B., Wang L., Sun L., Cao R., Combination therapy improves exercise capacity and reduces risk of clinical worsening in patients with pulmonary arterial hypertension: a meta-analysis. Journal of Cardiovascular Pharmacology 2012 60 4 342 346 2-s2.0-84867742487 10.1097/FJC.0b013e318262a793
54. Fox B. D., Shimony A., Langleben D., Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. The American Journal of Cardiology 2011 108 8 1177 1182 2-s2.0-84860404865 10.1016/j.amjcard.2011.06. 021
55. McLaughlin V. V., Archer S. L., Badesch D. B., Barst R. J., Farber H. W., Lindner J. R., Mathier M. A., McGoon M. D., Park M. H., Rosenson R. S., Rubin L. J., Tapson V. F., Varga J., ACCF/AHA 2009 Expert consensus document on pulmonary hypertension. A report of the American college of cardiology foundation task force on expert consensus documents and the American heart association developed in collaboration with the American college of chest physicians; American thoracic society, Inc.; and the pulmonary hypertension association. Journal of the American College of Cardiology 2009 53 17 1573 1619 2-s2.0-64849109410 10.1016/j.jacc.2009.01.004
56. Galiè N., Negro L., Simonneau G., The use of combination therapy in pulmonary arterial hypertension: new developments. European Respiratory Review 2009 18 113 148 153 2-s2.0-70049108513 10.1183/09059180.00003809
57. Paulin R., Courboulin A., Barrier M., Bonnet S., From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension. Journal of Molecular Medicine 2011 89 11 1089 1101 2-s2.0-80755153114 10.1007/s00109-011-0788-5
58. Kuwano K., Hashino A., Asaki T., Hamamoto T., Yamada T., Okubo K., Kuwabara K., 2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N- (methylsulfonyl) acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. Journal of Pharmacology and Experimental Therapeutics 2007 322 3 1181 1188 2-s2.0-34548101404 10.1124/jpet.107.124248 (Pubitemid 47295780)
59. Morrison K., Studer R., Ernst R., Haag F., Kauser K., Clozel M., Differential effects of selexipag and prostacyclin analogs in rat pulmonary artery. Journal of Pharmacology and Experimental Therapeutics 2012 343 3 547 555 2-s2.0-84869209570 10.1124/jpet.112.197152
60. Simonneau G., Torbicki A., Hoeper M. M., Delcroix M., Karlócai K., Galièe N., Degano B., Bonderman D., Kurzyna M., Efficace M., Giorgino R., Lang I. M., Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. European Respiratory Journal 2012 40 4 874 880 2-s2.0-84863528040 10.1183/09031936.00137511
61. Selexipag (ACT-293987) in pulmonary arterial hypertension, GRIPHON trial. Identifier NCT01106014, http://clinicaltrials.gov/
62. Blay J. Y., A decade of tyrosine kinase inhibitor therapy: historical and current perspectives on targeted therapy for GIST. Cancer Treatment Reviews 2011 37 5 373 384 2-s2.0-79957500033 10.1016/j.ctrv.2010.11.003
63. Chen Y., Peng C., Li D., Li S., Molecular and cellular bases of chronic myeloid leukemia. Protein and Cell 2010 1 2 124 132 2-s2.0-79953151232 10.1007/s13238-010-0016-z
64. Ohno R., Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Current Hematologic Malignancy Reports 2010 5 4 213 221 2-s2.0-77958506198 10.1007/s11899-010-0061-y
65. Baselga J., Targeting tyrosine kinases in cancer: the second wave. Science 2006 312 5777 1175 1178 2-s2.0-33744493376 10.1126/science.1125951 (Pubitemid 43801135)
66. Montani D., Perros F., Gambaryan N., Girerd B., Dorfmuller P., Price L. C., Huertas A., Hammad H., Lambrecht B., Simonneau G., Launay J., Cohen-Kaminsky S., Humbert M., C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. The American Journal of Respiratory and Critical Care Medicine 2011 184 1 116 123 2-s2.0-79957982619 10.1164/rccm.201006-0905OC
67. Humbert M., Monti G., Fartoukh M., Magnan A., Brenot F., Rain B., Capron F., Galanaud P., Duroux P., Simonneau G., Emilie D., Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. European Respiratory Journal 1998 11 3 554 559 2-s2.0-0031925331 (Pubitemid 28194842)
68. Schermuly R. T., Dony E., Ghofrani H. A., Pullamsetti S., Savai R., Roth M., Sydykov A., Lai Y. J., Weissmann N., Seeger W., Grimminger F., Reversal of experimental pulmonary hypertension by PDGF inhibition. Journal of Clinical Investigation 2005 115 10 2811 2821 2-s2.0-26444540768 10.1172/JCI24838 (Pubitemid 41434408)
69. Nakamura K., Akagi S., Ogawa A., Kusano K. F., Matsubara H., Miura D., Fuke S., Nishii N., Nagase S., Kohno K., Morita H., Oto T., Yamanaka R., Otsuka F., Miura A., Yutani C., Ohe T., Ito H., Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. International Journal of Cardiology 2012 159 2 100 106 2-s2.0-84864992329 10.1016/j.ijcard.2011.02.024
70. Ghofrani H., Morrell N. W., Hoeper M. M., Olschewski H., Peacock A. J., Barst R. J., Shapiro S., Golpon H., Toshner M., Grimminger F., Pascoe S., Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. The American Journal of Respiratory and Critical Care Medicine 2010 182 9 1171 1177 2-s2.0-77956709644 10.1164/rccm.201001-0123OC
71. Hoeper M. M., Barst R. J., Bourge R. C., Feldman J., Frost A. E., Galié N., Gómez-Sánchez M. A., Grimminger F., Grünig E., Hassoun P. M., Morrell N. W., Peacock A. J., Satoh T., Simonneau G., Tapson V. F., Torres F., Lawrence D., Quinn D. A., Ghofrani H., Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013 127 10 1128 1138 2-s2.0-84874948946 10.1161/CIRCULATIONAHA.112.000765
72. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., Tanaka C., Manley P., Rae P., Mietlowski W., Bochinski K., Hochhaus A., Griffin J. D., Hoelzer D., Albitar M., Dugan M., Cortes J., Alland L., Ottmann O. G., Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. The New England Journal of Medicine 2006 354 24 2542 2551 2-s2.0-33745086350 10.1056/NEJMoa055104 (Pubitemid 43882350)
73. Weisberg E., Manley P., Mestan J., Cowan-Jacob S., Ray A., Griffin J. D., AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. The British Journal of Cancer 2006 94 12 1765 1769 2-s2.0-33745114173 10.1038/sj.bjc.6603170 (Pubitemid 43882564)
74. Duggan N., Bonneau O., Hussey M., Comparison of effects of imatinib and nilotinib in a rodent model of pulmonary arterial hypertension. The American Journal of Respiratory and Critical Care Medicine 2010 181 A6304
75. Efficacy, safety, tolerability and pharmacokinetics (PK) of nilotinib (AMN107) in pulmonary arterial hypertension. Identifier NCT01179737, http://clinicaltrials.gov
76. Antoniu S. A., Targeting RhoA/ROCK pathway in pulmonary arterial hypertension. Expert Opinion on Therapeutic Targets 2012 16 4 355 363 2-s2.0-84859607472 10.1517/14728222.2012.671811
77. Abe K., Shimokawa H., Morikawa K., Uwatoku T., Oi K., Matsumoto Y., Hattori T., Nakashima Y., Kaibuchi K., Sueishi K., Takeshita A., Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circulation Research 2004 94 3 385 393 2-s2.0-10744222390 10.1161/01.RES.0000111804.34509.94 (Pubitemid 38240731)
78. 1 via the ERK signal pathway. Chinese Medical Journal 2011 124 19 3098 3104 2-s2.0-80053464564 10.3760/cma.j.issn.0366-6999.2011.19.027
79. Schwenke D. O., Pearson J. T., Sonobe T., Ishibashi-Ueda H., Shimouchi A., Kangawa K., Umetani K., Shirai M., Role of Rho-kinase signaling and endothelial dysfunction in modulating blood flow distribution in pulmonary hypertension. Journal of Applied Physiology 2011 110 4 901 908 2-s2.0-79954596642 10.1152/japplphysiol.01318.2010
80. Mouchaers K. T. B., Schalij I., de Boer M. A., Postmus P. E., van Hinsbergh V. W. M., van Nieuw Amerongen G. P., Vonk Noordegraaf A., van der Laarse W. J., Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. European Respiratory Journal 2010 36 4 800 807 2-s2.0-77957832881 10.1183/09031936.00130209
81. Chen C. I., Wu J. R., Dai Z. K., The beneficial effects of Rho-kinase inhibitor in pulmonary hypertension: from bench to bedside. Journal of Pediatric Respiratory Disease 2012 8 19 24
82. Fujita H., Fukumoto Y., Saji K., Sugimura K., Demachi J., Nawata J., Shimokawa H., Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart and Vessels 2010 25 2 144 149 2-s2.0-77950921360 10.1007/s00380-009-1176-8
83. Fukumoto Y., Matoba T., Ito A., Tanaka H., Kishi T., Hayashidani S., Abe K., Takeshita A., Shimokawa H., Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005 91 3 391 392 2-s2.0-14244260105 10.1136/hrt.2003.029470 (Pubitemid 40299237)
84. Ishikura K., Yamada N., Ito M., Ota S., Nakamura M., Isaka N., Nakano T., Beneficial acute effects of Rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circulation Journal 2006 70 2 174 178 2-s2.0-31644431508 10.1253/circj.70.174 (Pubitemid 43170128)
85. Dahal B. K., Kosanovic D., Pamarthi P. K., Sydykov A., Lai Y., Kast R., Schirok H., Stasch J., Ghofrani H. A., Weissmann N., Grimminger F., Seeger W., Schermuly R. T., Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. European Respiratory Journal 2010 36 4 808 818 2-s2.0-77957828780 10.1183/09031936.00140309
86. Maruno K., Absood A., Said S. I., VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells. The American Journal of Physiology-Lung Cellular and Molecular Physiology 1995 268 6 L1047 L1051 2-s2.0-0028812421
87. Gunaydin S., Imai Y., Takanashi Y., Seo K., Hagino I., Chang D., Shinoka T., The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: a comparative study with isoproteronol and nitroglycerine. Cardiovascular Surgery 2002 10 2 138 145 2-s2.0-0036118880 10.1016/S0967-2109(01)00126-0 (Pubitemid 34219061)
88. Petkov V., Gentscheva T., Schamberger C., Haberl I., Artl A., Andreae F., Mosgoeller W., The vasoactive intestinal peptide receptor turnover in pulmonary arteries indicates an important role for VIP in the rat lung circulation. Annals of the New York Academy of Sciences 2006 1070 481 483 2-s2.0-33746461310 10.1196/annals.1317.066 (Pubitemid 44126690)
89. Said S. I., Hamidi S. A., Dickman K. G., Szema A. M., Lyubsky S., Lin R. Z., Jiang Y., Chen J. J., Waschek J. A., Kort S., Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 2007 115 10 1260 1268 2-s2.0-33947721196 10.1161/CIRCULATIONAHA.106. 681718 (Pubitemid 46594770)
90. Leuchte H. H., Baezner C., Baumgartner R. A., Bevec D., Bacher G., Neurohr C., Behr J., Inhalation of vasoactive intestinal peptide in pulmonary hypertension. European Respiratory Journal 2008 32 5 1289 1294 2-s2.0-58849114113 10.1183/09031936.00050008
91. Galiè N., Boonstra A., Ewert R., Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH). The American Journal of Respiratory and Critical Care Medicine 2010 181 A2516
92. Said S. I., Vasoactive intestinal peptide in pulmonary arterial hypertension. The American Journal of Respiratory and Critical Care Medicine 2012 185 7 786 2-s2.0-84859495387
93. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., Witzenbichler B., Schatteman G., Isner J. M., Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997 275 5302 964 967 2-s2.0-0031019745 10.1126/science.275.5302.964 (Pubitemid 27087709)
94. Diller G., van Eijl S., Okonko D. O., Howard L. S., Ali O., Thum T., Wort S. J., Bédard E., Gibbs J. S. R., Bauersachs J., Hobbs A. J., Wilkins M. R., Gatzoulis M. A., Wharton J., Circulating endothelial progenitor cells in patients with eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation 2008 117 23 3020 3030 2-s2.0-46449088565 10.1161/CIRCULATIONAHA.108.769646
95. Junhui Z., Xingxiang W., Guosheng F., Yunpeng S., Furong Z., Junzhu C., Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension. Respiratory Medicine 2008 102 7 1073 1079 2-s2.0-44649145119 10.1016/j.rmed.2007.12.030
96. Asosingh K., Aldred M. A., Vasanji A., Drazba J., Sharp J., Farver C., Comhair S. A. A., Xu W., Licina L., Huang L., Anand-Apte B., Yoder M. C., Tuder R. M., Erzurum S. C., Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension. The American Journal of Pathology 2008 172 3 615 627 2-s2.0-40449086880 10.2353/ajpath.2008.070705 (Pubitemid 351354535)
97. Wang X. X., Zhang F. R., Shang Y. P., Zhu J., Xie X., Tao Q., Zhu J., Chen J., Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension. A pilot randomized controlled trial. Journal of the American College of Cardiology 2007 49 14 1566 1571 2-s2.0-34047108549 10.1016/j.jacc.2006.12.037 (Pubitemid 46517955)
98. Pulmonary hypertension assessment of cell therapy (PHACeT) trial. Identifier NCT00469027, http://clinicaltrials.gov
99. Klepetko W., Mayer E., Sandoval J., Trulock E. P., Vachiery J., Dartevelle P., Pepke-Zaba J., Jamieson S. W., Lang I., Corris P., Interventional and surgical modalities of treatment for pulmonary arterial hypertension. Journal of the American College of Cardiology 2004 43 supplement 12 73S 80S 2-s2.0-2942541465 10.1016/j.jacc.2004.02.039 (Pubitemid 38759721)
100. D'Alonzo G. E., Barst R. J., Ayres S. M., Bergofsky E. H., Brundage B. H., Detre K. M., Fishman A. P., Goldring R. M., Groves B. M., Kernis J. T., Levy P. S., Pietra G. G., Reid L. M., Reeves J. T., Rich S., Vreim C. E., Williams G. W., Wu M., Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Annals of Internal Medicine 1991 115 5 343 349 2-s2.0-0025837793
101. Baglini R., Atrial septostomy in patients with end-stage pulmonary hypertension. No more needles but wires, energy and close anatomical definition. Journal of Interventional Cardiology 2013 26 1 62 68 2-s2.0-84874110168 10.1111/j.1540-8183.2012.00759.x
102. Amaducci A., Lombardo L., Battaglia C., Baglini R., Atrial septostomy in patients with end-stage pulmonary hypertension: novel approach to trans-septal puncture. Eurointervention 2011 7 supplement M 389
103. Atrial septostomy for severe pulmonary arterial hypertension: evolving percutaneous approaches. Eurointervention 2012 8 supplement N 337
104. Sandoval J., Gaspar J., Peña H., Santos L. E., Córdova J., Del Valle K., Rodríguez A., Pulido T., Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension. European Respiratory Journal 2011 38 6 1343 1348 2-s2.0-82555189244 10.1183/09031936. 00072210
105. Chen S. L., Zhang F. F., Xu J., Xie D. J., Zhou L., Nguyen T., Stone G. W., Pulmonary artery denervation to treat pulmonary arterial hypertension. The single-center, prospective, first-in-man PADN-1 study. Journal of the American College of Cardiology 2013 62 12 1092 1100 10.1016/j.jacc.2013.05.075
106. Galiè N., Manes A., New treatment strategies for pulmonary arterial hypertension: hopes or hypes? Journal of the American College of Cardiology 2013 62 12 1101 1102 10.1016/j.jacc.2013.06.032